当前位置: 首页 >> 检索结果
101. Comparison of Procedural Outcomes of Lumenless Fixed-Helix Versus Stylet-Driven Extendable-Helix Lead Systems in Left Bundle Branch Pacing: COMPARE LBBP.
作者: Jenish P Shroff.;Anugrah Nair.;Deep Chandh Raja.;Sreevilasam P Abhilash.;Simon Fiorese.;Jonathan P Ariyaratnam.;Walter P Abhayaratna.;Prashanthan Sanders.;Pugazhendhi Vijayaraman.;Rajeev K Pathak.
来源: Circ Arrhythm Electrophysiol. 2024年17卷12期e013385页
Left bundle branch pacing (LBBP) has emerged as a safe and effective alternative to right ventricular pacing. Traditionally, LBBP is performed with lumenless lead (LLL); however, the use of stylet-driven lead (SDL) is on rise. We aimed to assess acute success and procedural outcomes of SDL versus LLL for LBBP.
102. CTCA Prior to Invasive Coronary Angiography in Patients With Previous Bypass Surgery: Patient-Related Outcomes, Imaging Resource Utilization, and Cardiac Events at 3 Years From the BYPASS-CTCA Trial.
作者: Matthew Kelham.;Anne-Marie Beirne.;Krishnaraj S Rathod.;Mervyn Andiapen.;Lucinda Wynne.;Annastazia E Learoyd.;Nasim Forooghi.;Rohini Ramaseshan.;James C Moon.;Ceri Davies.;Christos V Bourantas.;Andreas Baumbach.;Charlotte Manisty.;Andrew Wragg.;Amrita Ahluwalia.;Francesca Pugliese.;Anthony Mathur.;Daniel A Jones.
来源: Circ Cardiovasc Interv. 2024年17卷12期e014142页
In patients with previous coronary artery bypass grafting, computed tomography cardiac angiography (CTCA) before invasive coronary angiography (ICA) was demonstrated in the BYPASS-CTCA trial (Randomized Controlled Trial to Assess Whether Computed Tomography Cardiac Angiography Can Improve Invasive Coronary Angiography in Bypass Surgery Patients) to reduce procedure time and incidence of contrast-associated acute kidney injury, with greater levels of patient satisfaction. Patient-related outcomes, utilization of further diagnostic imaging resources, and longer-term incidence of major adverse cardiac events were key secondary end points not yet reported.
103. Quantifying Pill Disutility Associated With Starting Versus Continuing Cardioprotective Medication: A Randomized Experiment.
作者: Alexander Chaitoff.;Julie C Lauffenburger.;Nancy Haff.;Katharina Tabea Jungo.;Niteesh K Choudhry.
来源: Circ Cardiovasc Qual Outcomes. 2024年17卷11期e011069页
Quantifying patient-reported pill disutility is important for understanding the risk-benefit tradeoffs of taking medications. The objective of this study was to quantify and compare the pill disutility associated with starting a new medication and continuing an existing medication for cardiometabolic disease prevention in a sample of older adults in the United States.
104. Quality of Life in Subcutaneous or Transvenous Implantable Cardioverter-Defibrillator Patients: A Secondary Analysis of the PRAETORIAN Trial.
作者: Reinoud E Knops.;Jolien A de Veld.;Abdul Ghani.;Lucas V A Boersma.;Juergen Kuschyk.;Mikhael F El Chami.;Hendrik Bonnemeier.;Elijah R Behr.;Tom F Brouwer.;Stefan Kääb.;Suneet Mittal.;Shari Pepplinkhuizen.;Anne-Floor B E Quast.;Lonneke Smeding.;Willeke van der Stuijt.;Anouk de Weger.;Nick R Bijsterveld.;Sergio Richter.;Marc A Brouwer.;Joris R de Groot.;Kirsten M Kooiman.;Pier D Lambiase.;Petr Neuzil.;Kevin Vernooy.;Marco Alings.;Timothy R Betts.;Frank A L E Bracke.;Martin C Burke.;Jonas S S G de Jong.;David J Wright.;Ward P J Jansen.;Zachary I Whinnett.;Peter Nordbeck.;Michael Knaut.;Berit T Philbert.;Jurren M van Opstal.;Alexandru B Chicos.;Cornelis P Allaart.;Alida E Borger van der Burg.;Jose M Dizon.;Marc A Miller.;Dmitry Nemirovksy.;Ralf Surber.;Gaurav A Upadhyay.;Jan G P Tijssen.;Arthur A M Wilde.;Louise R A Olde Nordkamp.; .
来源: Circ Cardiovasc Qual Outcomes. 2024年17卷11期e010822页
The subcutaneous implantable cardioverter-defibrillator (S-ICD) was developed to overcome the risk of lead-related complications associated with the transvenous implantable cardioverter-defibrillator (TV-ICD). In contrast to the TV-ICD, the S-ICD is a completely extrathoracic device. Subsequently, complications differ between these 2 implantable cardioverter-defibrillators, which might impact patient perceptions of the therapies. This prespecified secondary analysis of the PRAETORIAN trial evaluates differences in quality of life.
105. Association of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab.
作者: Konstantinos C Koskinas.;Jonas Häner.;Yasushi Ueki.;Tatsuhiko Otsuka.;Jacob Lonborg.;Hiroki Shibutani.;Ryota Kakizaki.;Christoph Kaiser.;Robert-Jan van Geuns.;Anna S Ondracek.;Fabien Praz.;Maria Ambühl.;David Spirk.;Jonas Lanz.;Joost Daemen.;Dik Heg.;Manuel Mayr.;François Mach.;Stephan Windecker.;Thomas Engstrøm.;Irene M Lang.;Arnold von Eckardstein.;Sylvain Losdat.;Lorenz Räber.
来源: Circ Cardiovasc Imaging. 2024年17卷11期e016683页
Elevated Lp(a) (lipoprotein[a]) is a risk marker for atherosclerotic disease, but the underlying mechanisms remain elusive. We examined the association of Lp(a) with changes in coronary atherosclerosis following intensive lipid-lowering therapy.
106. Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity.
作者: Michael R Zile.;Barry A Borlaug.;Christopher M Kramer.;Seth J Baum.;Sheldon E Litwin.;Venu Menon.;Yang Ou.;Govinda J Weerakkody.;Karla C Hurt.;Chisom Kanu.;Masahiro Murakami.;Milton Packer.; .
来源: Circulation. 2025年151卷10期656-668页
Patients with heart failure with preserved ejection fraction and obesity have significant disability and frequent exacerbations of heart failure. We hypothesized that tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, would improve a comprehensive suite of clinical end points, including measures of health status, functional capacity, quality of life, exercise tolerance, patient well-being, and medication burden, in these patients.
107. Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial.
作者: Daniel P Judge.;Julian D Gillmore.;Kevin M Alexander.;Amrut V Ambardekar.;Francesco Cappelli.;Marianna Fontana.;Pablo García-Pavía.;Justin L Grodin.;Martha Grogan.;Mazen Hanna.;Ahmad Masri.;Jose Nativi-Nicolau.;Laura Obici.;Steen Hvitfeldt Poulsen.;Nitasha Sarswat.;Keyur Shah.;Prem Soman.;Ted Lystig.;Xiaofan Cao.;Kevin Wang.;Maria Lucia Pecoraro.;Jean-François Tamby.;Leonid Katz.;Uma Sinha.;Jonathan C Fox.;Mathew S Maurer.
来源: Circulation. 2025年151卷9期601-611页
In the phase 3 randomized controlled study ATTRibute-CM (Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy), acoramidis, a transthyretin stabilizer, demonstrated significant efficacy on the primary end point. Participants with transthyretin amyloid cardiomyopathy who completed ATTRibute-CM were invited to enroll in an open-label extension study (OLE). We report the efficacy and safety data of acoramidis in participants who completed ATTRibute-CM and enrolled in the ongoing OLE.
108. Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM.
作者: Milind Y Desai.;Kathy Wolski.;Anjali Owens.;Jeffrey B Geske.;Sara Saberi.;Andrew Wang.;Mark Sherrid.;Paul C Cremer.;Neal K Lakdawala.;Albree Tower-Rader.;David Fermin.;Srihari S Naidu.;Nicholas G Smedira.;Hartzell Schaff.;Zhiqun Gong.;Lana Mudarris.;Kathy Lampl.;Amy J Sehnert.;Steven E Nissen.; .
来源: Circulation. 2025年151卷19期1378-1390页
In severely symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM), VALOR-HCM trial (Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy [URL: https://clinicaltrials.gov; Unique identifier: NCT04349072]) reported that mavacamten reduced the short-term need for septal reduction therapy (SRT). The current report examined the longer-term effect of mavacamten through end of treatment at week 128.
109. Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial).
作者: Yugo Yamashita.;Takeshi Morimoto.;Nao Muraoka.;Wataru Shioyama.;Ryuki Chatani.;Tatsuhiro Shibata.;Yuji Nishimoto.;Yoshito Ogihara.;Kosuke Doi.;Maki Oi.;Taro Shiga.;Daisuke Sueta.;Kitae Kim.;Yasuhiro Tanabe.;Norimichi Koitabashi.;Takuma Takada.;Satoshi Ikeda.;Hitoshi Nakagawa.;Kengo Tsukahara.;Masaaki Shoji.;Jiro Sakamoto.;Shinji Hisatake.;Yutaka Ogino.;Masashi Fujita.;Naohiko Nakanishi.;Tomohiro Dohke.;Seiichi Hiramori.;Ryuzo Nawada.;Kazuhisa Kaneda.;Koh Ono.;Takeshi Kimura.; .
来源: Circulation. 2025年151卷9期589-600页
The optimal duration of anticoagulation therapy for patients with cancer and acute low-risk pulmonary embolism (PE) is clinically relevant, but evidence is lacking. Prolonged anticoagulation therapy could have a potential benefit for prevention of thrombotic events; however, it could also increase the risk of bleeding.
110. Renal Effects of Combination Phosphodiesterase V Inhibition and Low-Dose B-Type Natriuretic Peptide in Acute Heart Failure: A Randomized Clinical Trial.
作者: Scott A Hubers.;Sherry L Benike.;Bradley K Johnson.;Paul M McKie.;Christopher Scott.;Horng H Chen.
来源: Circ Heart Fail. 2024年17卷12期e011761页
Cardiorenal dysfunction with impaired cyclic GMP (cGMP) response is common in patients presenting with acute heart failure (HF). Type V phosphodiesterase (PDEV) is known to be upregulated in HF and may explain the dysfunction of renal response. The aim of this study was to determine whether B-type natriuretic peptide (BNP) alone or in combination with PDEV inhibition improves renal function and increases urinary sodium and cGMP excretion in acute HF.
111. Exercise Training in Patients With Hypertrophic Cardiomyopathy Without Left Ventricular Outflow Tract Obstruction: A Randomized Clinical Trial.
作者: Helga Lillian Gudmundsdottir.;Anna Axelsson Raja.;Kasper Rossing.;Hanne Rasmusen.;Martin Snoer.;Lars Juel Andersen.;Rikke Gottlieb.;Alex Hørby Christensen.;Henning Bundgaard.;Finn Gustafsson.;Jens Jakob Thune.
来源: Circulation. 2025年151卷2期132-144页
Patients with hypertrophic cardiomyopathy without left ventricular outflow tract obstruction commonly experience reduced exercise capacity. Physical training improves exercise capacity in these patients, but whether the underlying effects of exercise are a result of central hemodynamic or peripheral improvement is unclear. This study assessed whether exercise training reduces left ventricular filling pressure measured during exercise in patients with hypertrophic cardiomyopathy without left ventricular outflow tract obstruction.
112. Relative Benefit of Dual Versus Single Antiplatelet Therapy Among Patients With Atrial Fibrillation on Oral Anticoagulation According to Time After ACS and PCI: Insights From the AUGUSTUS Trial.
作者: Alexander C Fanaroff.;Daniel M Wojdyla.;Christopher B Granger.;Shaun G Goodman.;Ronald S Aronson.;Stephan Windecker.;Roxana Mehran.;John H Alexander.;Renato D Lopes.
来源: Circ Cardiovasc Interv. 2024年17卷11期e013596页
In the AUGUSTUS trial (An Open-Label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs Vitamin K Antagonist and Aspirin vs Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention), the combination of dual antiplatelet therapy plus oral anticoagulation increased the risk of bleeding without reducing ischemic events compared with a P2Y12 inhibitor plus oral anticoagulation among patients with atrial fibrillation and acute coronary syndrome or elective percutaneous coronary intervention. However, AUGUSTUS enrolled patients up to 14 days after acute coronary syndrome or percutaneous coronary intervention, and there may be a benefit to dual antiplatelet therapy plus oral anticoagulation early after an ischemic event.
113. Impact of a Chronic Total Occlusion on Outcomes After FFR-Guided PCI or Coronary Bypass Surgery: A FAME 3 Substudy.
作者: Hisao Otsuki.;Kuniaki Takahashi.;Frederik M Zimmermann.;Kreton Mavromatis.;Adel Aminian.;Nikola Jagic.;Jan-Henk E Dambrink.;Petr Kala.;Philip MacCarthy.;Nils Witt.;Yuhei Kobayashi.;Tatsunori Takahashi.;Y Joseph Woo.;Alan C Yeung.;Bernard De Bruyne.;Nico H J Pijls.;William F Fearon.; .
来源: Circ Cardiovasc Interv. 2024年17卷11期e014300页
The clinical impact of a chronic total occlusion (CTO) in patients with 3-vessel coronary artery disease undergoing fractional flow reserve-guided percutaneous coronary intervention (PCI) with current-generation drug-eluting stents or coronary artery bypass grafting (CABG) is unclear.
114. Preventing Allogeneic Stem Cell Transplant-Related Cardiovascular Dysfunction: ALLO-Active Trial.
作者: Hayley T Dillon.;Nicholas J Saner.;Tegan Ilsley.;David S Kliman.;Stephen J Foulkes.;Christian J Brakenridge.;Andrew Spencer.;Sharon Avery.;Piet Claus.;David W Dunstan.;Robin M Daly.;Steve F Fraser.;Neville Owen.;Brigid M Lynch.;Bronwyn A Kingwell.;Andre La Gerche.;Erin J Howden.
来源: Circulation. 2025年151卷4期292-308页
Allogeneic stem cell transplantation (allo-SCT) is an efficacious treatment for hematologic malignancies but can be complicated by cardiac dysfunction and exercise intolerance impacting quality of life and longevity. We conducted a randomized controlled trial testing whether a multicomponent activity intervention could attenuate reductions in cardiorespiratory fitness and exercise cardiac function (co-primary end points) in adults undergoing allo-SCT.
115. Large-Bore Mechanical Thrombectomy Versus Catheter-Directed Thrombolysis in the Management of Intermediate-Risk Pulmonary Embolism: Primary Results of the PEERLESS Randomized Controlled Trial.
作者: Wissam A Jaber.;Carin F Gonsalves.;Stefan Stortecky.;Samuel Horr.;Orestis Pappas.;Ripal T Gandhi.;Keith Pereira.;Jay Giri.;Sameer J Khandhar.;Khawaja Afzal Ammar.;David M Lasorda.;Brian Stegman.;Lucas Busch.;David J Dexter.;Ezana M Azene.;Nikhil Daga.;Fakhir Elmasri.;Chandra R Kunavarapu.;Mark E Rea.;Joseph S Rossi.;Joseph Campbell.;Jonathan Lindquist.;Adam Raskin.;Jason C Smith.;Thomas M Tamlyn.;Gabriel A Hernandez.;Parth Rali.;Torrey R Schmidt.;Jeffrey T Bruckel.;Juan C Camacho.;Jun Li.;Samy Selim.;Catalin Toma.;Sukhdeep Singh Basra.;Brian A Bergmark.;Bhavraj Khalsa.;David M Zlotnick.;Jordan Castle.;David J O'Connor.;C Michael Gibson.; .
来源: Circulation. 2025年151卷5期260-273页
There are a lack of randomized controlled trial data comparing outcomes of different catheter-based interventions for intermediate-risk pulmonary embolism.
116. Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Coronary Artery Disease.
作者: Michael J Foley.;Christopher A Rajkumar.;Fiyyaz Ahmed-Jushuf.;Florentina Simader.;Shayna Chotai.;Henry Seligman.;Krzysztof Macierzanka.;John R Davies.;Thomas R Keeble.;Peter O'Kane.;Peter Haworth.;Helen Routledge.;Tushar Kotecha.;Gerald Clesham.;Rupert Williams.;Jehangir Din.;Sukhjinder S Nijjer.;Nick Curzen.;Manas Sinha.;Ricardo Petraco.;James Spratt.;Sayan Sen.;Graham D Cole.;Frank E Harrell.;James P Howard.;Darrel P Francis.;Matthew J Shun-Shin.;Rasha Al-Lamee.; .
来源: Circulation. 2025年151卷3期202-214页
ORBITA-2 (the Placebo-Controlled Trial of Percutaneous Coronary Intervention for the Relief of Stable Angina) provided evidence for the role of percutaneous coronary intervention (PCI) for angina relief in stable coronary artery disease. Fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) are often used to guide PCI; however, their ability to predict placebo-controlled angina improvement is unknown.
117. Microaxial Flow Pump Use and Renal Outcomes in Infarct-Related Cardiogenic Shock: A Secondary Analysis of the DanGer Shock Trial.
作者: Elric Zweck.;Christian Hassager.;Rasmus P Beske.;Lisette O Jensen.;Hans Eiskjær.;Norman Mangner.;Amin Polzin.;P Christian Schulze.;Carsten Skurk.;Peter Nordbeck.;Peter Clemmensen.;Vasileios Panoulas.;Sebastian Zimmer.;Andreas Schäfer.;Malte Kelm.;Thomas Engstrøm.;Lene Holmvang.;Anders Junker.;Henrik Schmidt.;Christian J Terkelsen.;Axel Linke.;Ralf Westenfeld.;Jacob E Møller.; .
来源: Circulation. 2024年150卷25期1990-2003页
In DanGer Shock (the Danish-German Cardiogenic Shock trial), use of a microaxial flow pump (mAFP) in patients with ST-segment-elevation myocardial infarction-related cardiogenic shock led to lower all-cause mortality but higher rates of renal replacement therapy (RRT). In this prespecified analysis, rates and predictors of acute kidney injury (AKI) and RRT were assessed.
118. Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.
作者: Li Shen.;Pooja Dewan.;João Pedro Ferreira.;Jonathan W Cunningham.;Pardeep S Jhund.;Inder S Anand.;Alvin Chandra.;Lu-May Chiang.;Brian Claggett.;Akshay S Desai.;Jianjian Gong.;Carolyn S P Lam.;Martin P Lefkowitz.;Aldo P Maggioni.;Felipe Martinez.;Milton Packer.;Margaret M Redfield.;Jean L Rouleau.;Dirk J van Veldhuisen.;Faiez Zannad.;Michael R Zile.;Scott D Solomon.;John J V McMurray.
来源: Circulation. 2024年150卷24期1913-1927页
Cognitive impairment is common in patients with heart failure and preserved ejection fraction but its clinical correlates and prognostic associations are poorly understood.
119. Three-Year Outcomes Following TAVR in Younger (<75 Years) Low-Surgical-Risk Severe Aortic Stenosis Patients.
作者: Thomas Modine.;Didier Tchétché.;Nicolas M Van Mieghem.;G Michael Deeb.;Stanley J Chetcuti.;Steven J Yakubov.;Paul Sorajja.;Hemal Gada.;Mubashir Mumtaz.;Basel Ramlawi.;Tanvir Bajwa.;John Crouch.;Paul S Teirstein.;Neal S Kleiman.;Ayman Iskander.;Rodrigo Bagur.;Michael W A Chu.;Pierre Berthoumieu.;Arnaud Sudre.;Rik Adrichem.;Saki Ito.;Jian Huang.;Jeffrey J Popma.;John K Forrest.;Michael J Reardon.
来源: Circ Cardiovasc Interv. 2024年17卷11期e014018页
Transcatheter aortic valve replacement (TAVR) is an alternative to surgery in patients with severe aortic stenosis, but data are limited on younger, low-risk patients. This analysis compares outcomes in low-surgical-risk patients aged <75 years receiving TAVR versus surgery.
120. Absence of Kidney Tubular Injury in Patients With Acute Heart Failure With Acute Kidney Injury.
作者: Stephen Duff.;Nicholas Wettersten.;Yu Horiuchi.;Dirk J van Veldhuisen.;Sagar Raturi.;Ruairi Irwin.;Jean Maxime Côté.;Alan Maisel.;Joachim H Ix.;Patrick T Murray.
来源: Circ Heart Fail. 2024年17卷11期e011751页
Worsening renal function (WRF) is common in hospitalized patients being treated for acute heart failure. However, discriminating clinically significant WRF remains challenging. In patients hospitalized with acute heart failure, we evaluated if blood and urine biomarkers of cardiac and kidney dysfunction were associated with adverse outcomes.
|